Original Publication Date: 16 December, 2013
Publication / Source: Future Oncology
Authors: Alessandro Satta, Delia Mezzanzanica, Fabio Turatti, Silvana Canevari & Mariangela Figini
T cells are the most potent cells of the immune system; however, they fail in the immunosurveillance of tumors. In previous decades, scientists began studying methods to take advantage of T-cell potency in cancer therapy by redirecting them against tumors independently from the T-cell receptor-defined specificity. Among different approaches, the most promising are the use of bispecific antibodies and T-cell engineering to create chimeric antigen receptors.